Literature DB >> 17975715

PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer.

Charlotte Kristiansen1, Annika Loft, Anne K Berthelsen, Jesper Graff, Jan Lindebjerg, Claus Bisgaard, Anders Jakobsen.   

Abstract

PURPOSE: The objective of this study was to investigate the possibility of using positron emission tomography/computer tomography to predict the histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiation.
METHODS: The study included 30 patients with locally advanced rectal adenocarcinoma treated with a combination of radiotherapy and concurrent Uftoral (uracil, tegafur) and leucovorine. All patients were evaluated by positron emission tomography/computer tomography scan seven weeks after end of chemoradiation, and the results were compared to histopathologic tumor regression as the "standard." The pathologic response was quantified by tumor regression grade.
RESULTS: Positron emission tomography/computer tomography correctly identified six of eight patients (specificity 75 percent) with complete pathologic response. However, the sensitivity of positron emission tomography/computer tomography was only 45 percent and the accuracy 53 percent. The positive and negative predictive values were 83 and 33 percent, respectively.
CONCLUSIONS: We conclude that positron emission tomography/computer tomography performed seven weeks after the end of chemoradiation is not able to predict the histopathologic response in locally advanced rectal cancer. There is an obvious need for other complementary methods especially with respect to the low sensitivity of positron emission tomography/computer tomography.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975715     DOI: 10.1007/s10350-007-9095-1

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  18 in total

1.  Positron emission tomography as predictor of rectal cancer response during or following neoadjuvant chemoradiation.

Authors:  Shane Hopkins; Marwan Fakih; Gary Y Yang
Journal:  World J Gastrointest Oncol       Date:  2010-05-15

Review 2.  Adaptive radiation dose escalation in rectal adenocarcinoma: a review.

Authors:  Jonathan D Van Wickle; Eric S Paulson; Jerome C Landry; Beth A Erickson; William A Hall
Journal:  J Gastrointest Oncol       Date:  2017-10

Review 3.  Management of the Complete Clinical Response.

Authors:  Angelita Habr-Gama; Guilherme Pagin São Julião; Bruna Borba Vailati; Ivana Castro; Debora Raffaele
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

4.  Report from the 19th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Winnipeg, Manitoba; 29-30 September 2017.

Authors:  C A Kim; S Ahmed; S Ahmed; B Brunet; H Chalchal; R Deobald; C Doll; M P Dupre; V Gordon; R M Lee-Ying; H Lim; D Liu; J M Loree; J P McGhie; K Mulder; J Park; B Yip; R P Wong; A Zaidi
Journal:  Curr Oncol       Date:  2018-08-14       Impact factor: 3.677

5.  Fifteen different 18F-FDG PET/CT qualitative and quantitative parameters investigated as pathological response predictors of locally advanced rectal cancer treated by neoadjuvant chemoradiation therapy.

Authors:  Anna Margherita Maffione; Alice Ferretti; Gaia Grassetto; Elena Bellan; Carlo Capirci; Sotirios Chondrogiannis; Marcello Gava; Maria Cristina Marzola; Lucia Rampin; Claudia Bondesan; Patrick M Colletti; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

6.  Combined value of apparent diffusion coefficient-standardized uptake value max in evaluation of post-treated locally advanced rectal cancer.

Authors:  Davide Ippolito; Davide Fior; Chiara Trattenero; Elena De Ponti; Silvia Drago; Luca Guerra; Cammillo Talei Franzesi; Sandro Sironi
Journal:  World J Radiol       Date:  2015-12-28

7.  Laboratory blood data have a significant impact on tumor response and outcome in preoperative chemoradiotherapy for advanced rectal cancer.

Authors:  Koji Yasuda; Eiji Sunami; Kazushige Kawai; Hirokazu Nagawa; Joji Kitayama
Journal:  J Gastrointest Cancer       Date:  2012-06

8.  Pretreatment identification of patients likely to have pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer.

Authors:  Frederik J van der Sluis; Henderik L van Westreenen; Boudewijn van Etten; Barbara L van Leeuwen; Geertruida H de Bock
Journal:  Int J Colorectal Dis       Date:  2017-12-15       Impact factor: 2.571

9.  The value of 18F-FDG PET/CT for assessing the response to neoadjuvant therapy in locally advanced rectal cancer.

Authors:  M J Murcia Duréndez; L Frutos Esteban; J Luján; M D Frutos; G Valero; J L Navarro Fernández; L Mohamed Salem; G Ruiz Merino; M A Claver Valderas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-19       Impact factor: 9.236

10.  Progress in rectal cancer treatment.

Authors:  Wim P Ceelen
Journal:  ISRN Gastroenterol       Date:  2012-08-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.